CTOs on the Move

480 Biomedical

www.480biomedical.com

 
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

480 Biomedical raised $10M on 06/01/2015

Similar Companies

PlateletBio

PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics.

Corventis

Corventis is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Millendo

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).

CalciMedica

CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.

Silk Technologies

SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications. The company`s patented SDP material is currently being developed as a novel compound for the treatment of patients with dry eye disease. SILKTECH is based in Plymouth, MN and is financially backed by a combination of angels, grants and recently from a financing round by Skyview Ventures LLC.